2 weeks Ago By Defense World Staff
Legal & General Group Plc lifted its stake in shares of Gilead Sciences, Inc. ( NASDAQ:GILD – Free Report ) by 0.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The firm owned 12,414,268 shares of the biopharmaceutical company’s stock after acquiring an additional 93,068 shares during the period. Legal & General Group Plc owned 1.00% of Gilead Sciences worth $851,743,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Vanguard Group Inc. raised its holdings in Gilead Sciences by 2.
6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after buying an additional 2,910,147 shares during the period.
Capital World Investors boosted its position in shares of Gilead Sciences by 1.4% during the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock worth $6,189,435,000 after purchasing an additional 1,133,281 shares during the period.
Capital Research Global Investors raised its position in Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after purchasing an additional 1,589,240 shares during the period.
Wellington Management Group LLP lifted its stake in Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after purchasing an additional 2,350,550 shares in the last quarter.
Finally, Dimensional Fund Advisors LP raised its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock valued at $714,421,000 after buying an additional 268,208 shares during the period.
Institutional investors and hedge funds own 83.67% of the company’s stock. Analyst Ratings Changes GILD has been the topic of a number of recent research reports.
Piper Sandler reiterated an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research note on Wednesday, September 11th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $72.
00 to $74.00 and gave the stock a “sector perform” rating in a report on Wednesday, September 4th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.
00 price target for the company in a research note on Monday, July 8th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $70.
00 target price on shares of Gilead Sciences in a research note on Monday, September 16th. Twelve equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.
com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.06. Gilead Sciences Stock Up 1.
0 % Gilead Sciences stock opened at $83.04 on Friday. The company has a market capitalization of $103.
46 billion, a P/E ratio of 230.67, a PEG ratio of 2.91 and a beta of 0.
18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.
95 and a current ratio of 1.14. Gilead Sciences, Inc.
has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.
The stock has a 50-day simple moving average of $77.83 and a 200-day simple moving average of $71.53.
Gilead Sciences ( NASDAQ:GILD – Get Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.
61 by $0.40. The company had revenue of $6.
95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.
34% and a net margin of 3.79%. Equities research analysts expect that Gilead Sciences, Inc.
will post 3.78 earnings per share for the current year. Gilead Sciences Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th.
Shareholders of record on Friday, September 13th will be given a dividend of $0.77 per share. This represents a $3.
08 annualized dividend and a yield of 3.71%. The ex-dividend date is Friday, September 13th.
Gilead Sciences’s payout ratio is currently 855.56%. Insider Buying and Selling at Gilead Sciences In related news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th.
The stock was sold at an average price of $73.98, for a total transaction of $406,150.20.
Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link .
In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.
00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40.
The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.
98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.
42. The disclosure for this sale can be found here . Over the last three months, insiders have sold 36,847 shares of company stock worth $3,002,940.
0.16% of the stock is owned by company insiders. About Gilead Sciences ( Free Report ) Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. Read More Five stocks we like better than Gilead Sciences Insider Trades May Not Tell You What You Think REITs on the Rise After Rate Cuts: Where to Invest Now Top Stocks Investing in 5G Technology Is Viking Therapeutics Ready For Another Surge? The How And Why of Investing in Oil Stocks AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
